Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClouDr GroupFRA:H3L 48 Gross Margin % is 60.78% as of Dec. 2025, which is 129% above its 10-year median of 26.51. GuruFocus rates FRA:H3L with a GF Score™ of 48/100 and a GF Value™ of €0.08. The stock has 9 warning signs investors should review. Among 118 Medical Distribution companies, ClouDr Group ranks better than 89.83% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ClouDr Group had a gross margin of 60.78% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ClouDr Group Gross Margin % Related Terms
ClouDr Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for ClouDr Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:H3L vs MCK, COR, CAH: Gross Margin % Comparison
For the Medical Distribution subindustry, ClouDr Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClouDr Group Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ClouDr Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ClouDr Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ClouDr Group (FRA:H3L) has a Gross Margin % of 60.78% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on ClouDr Group and its competitors. This is 129% above median its historical median of 26.51. Over the past decade, ClouDr Group's Gross Margin % has ranged from 11.74 to 47.81. According to the industry distribution chart, ClouDr Group ranks #12 out of 118 companies in the Medical Distribution industry, placing it in the top 10.2%.
Is ClouDr Group's Gross Margin % too high?
ClouDr Group's current Gross Margin % of 60.78% is 129% above median its 10-year median of 26.51. Over the past 10 years, this metric has ranged from a low of 11.74 to a high of 47.81. The Medical Distribution industry median Gross Margin % is 15.02. ClouDr Group's value of 60.78% is 304.8% above this industry median. Based on the distribution chart, ClouDr Group ranks #12 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, ClouDr Group has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's Gross Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, ClouDr Group ranks #12 out of 118 companies for Gross Margin %. This places ClouDr Group in the top 10% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 15.02. ClouDr Group's value of 60.78% is 304.8% above this benchmark. Historically, ClouDr Group's own Gross Margin % has ranged from 11.74 to 47.81 over the past decade. While the company's 10-year median is 26.51 vs. the industry median of 15.02, ClouDr Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 15.02, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ClouDr Group's current Gross Margin % of 60.78% is 304.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ClouDr Group and its competitors. For the Medical Distribution industry, the median Gross Margin % is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClouDr Group's current Gross Margin % is 60.78%, which is 129% above median its own 10-year median of 26.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
ClouDr Group (FRA:H3L) has a current Gross Margin % of 60.78%. The stock's GF Value™ is €0.08, compared to a current price of €0.05 — trading 36.9% below its estimated fair value. The current Gross Margin % is 60.78%, which is 129% above median its 10-year median of 26.51 and 304.8% above the Medical Distribution industry median of 15.02. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ClouDr Group (FRA:H3L), the current Gross Margin % is 60.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClouDr Group (FRA:H3L) Overvalued in 2026?
Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued.
The current stock price of €0.05 is trading 36.9% below its estimated GF Value™ of €0.08.
Key valuation signals for FRA:H3L:
Gross Margin %: 60.78% (129% above median its 10-year median of 26.51)
GF Value™: €0.08 vs. price of €0.05 (36.9% below fair value)
Industry Position: 304.8% above the Medical Distribution median (#12 of 118)
No single metric tells the full story. See the FRA:H3L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score
Get the complete analysis for FRA:H3L
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H3L has been successfully added to your 
